Efficacy and safety of omalizumab in Japanese and Korean patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): Results from the phase III POLARIS study

被引：0
|
作者：
Hide, Michihiro
Park, Hae-Sim [1 ]
Igarashi, Atsuyuki [2 ]
Ye, Young Min [1 ]
Kim, Tae-Bum [3 ]
Yagami, Akiko [4 ]
Lee, Jae-Hyun
Fukunaga, Atsushi [5 ]
Khalil, Sam [6 ]
机构：
[1] Ajou Univ, Sch Med, Suwon, South Korea
[2] NTT Med Ctr Tokyo, Tokyo, Japan
[3] Asan Med Ctr, Seoul, South Korea
[4] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan
[5] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan
[6] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
4820
引用
收藏
页码：AB112 / AB112
页数：1
相关论文
共 50 条
  • [1] Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
    Yan, Che-Wen
    Cho, Yung-Tsu
    Chu, Chia-Yu
    DERMATOLOGICA SINICA, 2017, 35 (04) : 182 - 186
  • [2] Efficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
    Casale, Thomas
    Maurer, Marcus
    Hsieh, Hsin-Ju
    Canvin, Janice
    Saini, Sarbjit S.
    Grattan, Clive
    Gimenez-Arnau, Ana
    Kaplan, Allen P.
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB327 - AB327
  • [3] Clinical Characteristics of Adolescent Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) in Three Phase III Studies with Omalizumab
    Goldstein, Stanley
    Skoner, David P.
    Ortiz, Benjamin
    Kianifard, Farid
    Vu, Julie
    Mendelson, Meryl
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB129 - AB129
  • [4] Omalizumab effectively reduces angioedema episodes in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU)
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Canvin, J.
    Maurer, M.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 18 - 18
  • [5] Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria
    Michihiro, Hide
    Hae-Sim, Park
    Atsuyuki, Igarashi
    Young-Min, Ye
    Tae-Bum, Kim
    Akiko, Yagami
    Jooyoung, Roh
    Jae-Hyun, Lee
    Yuko, Chinuki
    Woong, Youn Sang
    Soo-Keol, Lee
    Naoko, Inomata
    Jeong-Hee, Choi
    Atsushi, Fukunaga
    Junyi, Wang
    Soichiro, Matsushima
    Steve, Greenberg
    Sam, Khalil
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 87 (01) : 70 - 78
  • [6] Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
    Hide, Michihiro
    Igarashi, Atsuyuki
    Yagami, Akiko
    Chinuki, Yuko
    Inomata, Naoko
    Fukunaga, Atsushi
    Kaiser, Guenther
    Wang, Junyi
    Matsushima, Soichiro
    Greenberg, Steven
    Khalil, Sam
    ALLERGOLOGY INTERNATIONAL, 2018, 67 (02) : 243 - 252
  • [7] Baseline Characteristics of Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Enrolled in a Phase III, Randomized, Placebo-Controlled Trial of Omalizumab
    Rosen, Karin
    Hsieh, Hsin-Ju
    Georgiou, Panayiotis
    Casale, Thomas
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB29 - AB29
  • [8] Clinical profile of patients with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) in phase III omalizumab studies: Analyses according to the presence or absence of angioedema
    Sofen, Howard
    Mendelson, Meryl
    Vu, Julie
    Kianifard, Farid
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB43 - AB43
  • [9] REAL-WORLD TREATMENT PATTERNS OF OMALIZUMAB IN CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA (CIU/CSU) PATIENTS IN THE UNITED STATES
    Eghrari-Sabet, J.
    Sher, E.
    Lefebvre, P.
    Pilon, D.
    Zhdanava, M.
    Balp, M.
    Kavati, A.
    Ortiz, B.
    Bernstein, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S42 - S42
  • [10] Safety and tolerability of omalizumab in patients with chronic idiopathic/spontaneous urticaria: Results from the OPTIMA study
    Sussman, Gordon
    Hebert, Jacques
    Gooderham, Melinda
    Gulliver, Wayne
    Lynde, Charles W.
    Papp, Kim A.
    Yang, William H.
    de Takacsy, Frederica
    Chambenoit, Olivier
    Rihakova, Lenka
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB250 - AB250
12345